In the future, other strategies may be more effective, such as tumour selective metabolic reprogramming, via mitochondria oxidative phosphorylation depression, which down-regulates PD-L1 and reactivates immunotherapy, opening a potential window for mitochondrial immunotherapy [100]. This evidence concerns the gene CD274 and neoplasm.